Skip to main content

Advertisement

SpringerLink
Log in

Photodynamic therapy in the biliary tract

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Biliary tract cancers are rare malignancies usually characterized by slow growth and a low propensity for metastasis. Despite the relatively localized nature of these cancers, the only therapeutic measure with curative potential to date is surgical intervention. Because symptoms occur late, the diagnosis is rarely made at an early stage, and therefore only about half of the patients can have curative surgery. Patients with advanced disease face a dismal prognosis because palliative treatment options are limited. This review outlines recent advances in treatment of biliary cancer. Encouraging results from prospective, single-arm phase II trials of photodynamic therapy in nonresectable cholangiocarcinoma suggest considerable promise for this new palliative treatment modality. However, the apparent benefit of photodynamic therapy on survival, jaundice, and quality of life must be confirmed in a randomized multicenter trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7–33.

    PubMed  CAS  Google Scholar 

  2. Holzinger F, Z`graggen K, Buchler MW: Mechanisms of biliary carcinogenesis: a pathogenic multistage cascade toward cholangiocarcinoma. Ann Oncol 1999, 10(suppl 4):122–126.

    Article  PubMed  Google Scholar 

  3. DeGroen PC, Gores GJ, LaRusso NF, et al.: Biliary tract cancers. N Engl J Med 1999, 341:1368–1378.

    Article  CAS  Google Scholar 

  4. Chapman RW: Risk factors for biliary tract carcinogenesis. Ann Oncol 1999, 10(suppl 4):308–311.

    Article  PubMed  Google Scholar 

  5. Abdalla EK, Forsmark CE, Lauwers GY, et al.: Monolobular Caroli's and cholangiocarcinoma. HPB Surg 1999, 11:271–277.

    PubMed  CAS  Google Scholar 

  6. Ekborn A, Hsieh CC, Yuen J, et al.: Risk of extrahepatic bile duct cancer after cholecystectomy. Lancet 1993, 342:1262–1265.

    Article  Google Scholar 

  7. Chijiiwa K, Ichimiya H, Kuroki S, et al.: Late development of cholangiocarcinoma after the treatment of hepatolithiasis. Surg Gynecol Obstet 1993, 177:279–282.

    PubMed  CAS  Google Scholar 

  8. Caygill CP, Hill MJ, Braddick M, Sharp JCM: Cancer mortality in chronic typhoid and parathypoid carriers. Lancet 1994, 343:83–84.

    Article  PubMed  CAS  Google Scholar 

  9. Hakameda K, Sasaki M, Endoh M, et al.: Late development of bile duct cancer after sphincteroplasty: a ten-to-twentytwo- year follow-up study. Surgery 1997, 121:488–492.

    Article  Google Scholar 

  10. Khan ZR, Neugut AI, Ahsan H, Chabot JA: Risk factors for biliary tract cancers. Am J Gastroenterol 1999, 94:149–152.

    Article  PubMed  CAS  Google Scholar 

  11. Lee CS: Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and ki-67 antigen immunorectivity in in situ and invasive carcinomas of the extrahepatic biliary tract. Cancer 1996, 78:1881–1887.

    Article  PubMed  CAS  Google Scholar 

  12. Itoi T, Takei K, Shinohara Y, Takeda K, et al.: K-ras codon 12 and p53 mutations in biopsy specimens and bile from biliary tract cancers. Pathol Int 1999, 49:30–37.

    Article  PubMed  CAS  Google Scholar 

  13. Arora DS, Ramsdale J, Lodge JP, Wyatt JI: P53 but not bcl-2 is expressed by most cholangiocarcinomas: a study of 28 cases. Histopathology 1999, 34:497–501.

    Article  PubMed  CAS  Google Scholar 

  14. Korner T, Kropf J, Hackler R, et al.: Fibronectin in human bile fluid for diagnosis of malignant biliary diseases. Hepatology 1996, 23:423–428.

    PubMed  CAS  Google Scholar 

  15. Ashida K, Tereda T, Kitamura Y, Kaibara N: Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 1998, 27:974–982.

    Article  PubMed  CAS  Google Scholar 

  16. Goydos JS, Brumfield AM, Frezza E, et al.: Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 1998, 227:398–404.

    Article  PubMed  CAS  Google Scholar 

  17. Jaiswal M, LaRusso NF, Burgart LJ, et al.: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000, 50:184–190.

    Google Scholar 

  18. Bismuth H, Nakache R, Diamond T: Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992, 215:31–38.

    Article  PubMed  CAS  Google Scholar 

  19. Nakeeb A, Pitt HA, Sohn TA, et al.: Cholangiocarcinoma: a spectrum of intrahepatic, perihilar and distal tumors. Ann Surg 1996, 224:463–473.

    Article  PubMed  CAS  Google Scholar 

  20. Kosuge T, Yamamoto J, Shimada K, et al.: Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999, 230:663–671.

    Article  PubMed  CAS  Google Scholar 

  21. Jonas S, Kling N, Guckelberger O, et al.: Orthotopic liver transplantation after extended bile duct resection as treatment of hilar cholangiocarcinoma: first long-term results. Transpl Int 1998, 11(suppl 1):206–208.

    Article  Google Scholar 

  22. Su CH, Tsay SH, Wu CC, et al.: Factors influencing postoperative morbidiity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996, 223:384–394.

    Article  PubMed  CAS  Google Scholar 

  23. Luman W, Cull A, Palmer KR: Quality of life in patients stented for malignant biliary obstructions. Eur J Gastroenterol Hepatol 1997, 9:481–484.

    PubMed  CAS  Google Scholar 

  24. Ballinger AB, McHugh M, Catnach SM, et al.: Symptom relief and quality of life after stenting for malignant bile duct obstruction. Gut 1994, 35:467–470.

    PubMed  CAS  Google Scholar 

  25. Smith AC, Dowsett JF, Russell RCG, et al.: Randomized trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet 1994, 344:1655–1660.

    Article  PubMed  CAS  Google Scholar 

  26. Davids PH, Groen AK, Rauws EA, et al.: Randomized trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992, 340:1488–1492.

    Article  PubMed  CAS  Google Scholar 

  27. Prat F, Chapat O, Ducot B, et al.: A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 1998, 47:1–7. Although metallic stents remain patent longer than plastic stents, the overall survival time of patients with biliary malignancies cannot be prolonged.

    Article  PubMed  CAS  Google Scholar 

  28. Ducreux M, Liguory CL, Lefebre F, et al.: Management of malignant hilar biliary obstruction by endoscopy. Dig Dis Sci 1992, 37:778–783.

    Article  PubMed  CAS  Google Scholar 

  29. Polydorou A, Cairns SR, Dowsett J, et al.: Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion. Gut 1991, 32:685–689.

    PubMed  CAS  Google Scholar 

  30. Chang WH, Kortan P, Haber GB: Outcome in patients with bifurcation tumors who undergo unilateral vs. bilateral hepatic duct drainage. Gastrointest Endosc 1998, 47:354–362. The overall median survival in type III biliary tract tumors in this trial was 46 days. The best survival was noted in those patients with bilateral drainage, and the worst survival in those with cholangiographic opacification of both lobes but drainage of only one.

    Article  PubMed  CAS  Google Scholar 

  31. Tsujino K, Landry JC, Smith RG, et al.: Definitive radiation therapy for extrahepatic bile duct carcinoma. Radiology 1995, 196:275–280.

    PubMed  CAS  Google Scholar 

  32. Leung JT, Kuan R: Intraluminal brachytherapy in the treatment of bile duct carcinomas. Australas Radiol 1997, 41:151–154.

    PubMed  CAS  Google Scholar 

  33. Bowling TE, Galbraith SM, Hatfield ARW, et al.: A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996, 39:852–855.

    PubMed  CAS  Google Scholar 

  34. Hejna A, Pruckmayer M, Raderer M: The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 1998, 34:977–986.

    Article  PubMed  CAS  Google Scholar 

  35. vanGroeningen CJ: Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer. Ann Oncol 1999, 10:305–307. The data on the effect of chemotherapy in the biliary tract is sparse but does not suggest that it leads to results that are superior to those from supportive care alone. Likewise, there is no literature to support the routine application of regional chemotherapy in this type of tumor.

    Article  PubMed  Google Scholar 

  36. Raderer M, Hejan MH, Valencak JB, et al.: Two consecutive phase II studies of 5-fluorouracil/leucoverin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999, 56:177–180.

    Article  PubMed  CAS  Google Scholar 

  37. Lipson RL, Baldes EJ, Olsen AM: The use of a derivative of hematoporphyrin in tumor detection. J Natl Cancer Inst 1961, 26:1–11.

    PubMed  CAS  Google Scholar 

  38. Kato H, Kawaguchi M, Konaka C: Evaluation of PDT in gastric cancer. Laser Med Sci 1986, 1:67–74.

    Article  Google Scholar 

  39. Foote C: Definition of type I and type II photosensitized oxidation. Photochem Photobiol 1991, 54:659.

    PubMed  CAS  Google Scholar 

  40. Fingar VH, Wiemann TJ: Studies on the mechanism of photodynamic therapy induced tumor destruction. Proc SPIE: Photodynamic Therapy Mechanism II 1990, 1203:168–177.

    Google Scholar 

  41. Henderson BW, Donovan JM: Release of prostaglandin E2 from cells by photodynamic treatment in vitro. Cancer Res 1989, 49:6869–6890.

    Google Scholar 

  42. Nseyo UO, Whalen RK, Duncan MR, et al.: Urinary cytokines following photodynamic therapy of bladder cancer: a preliminary report. Urology 1990, 36:167–171.

    Article  PubMed  CAS  Google Scholar 

  43. McCaughan JS Jr, Mertens BF, Cho CH, et al.: Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. Arch Surg 1991, 126:111–113.

    PubMed  Google Scholar 

  44. Ortner MA, Liebetruth J, Schreiber ST, et al.: Photodynamic therapy of non-resectable cholangiocarcinoma. Gastroenterology 1998, 114:536–542. Report of successful PDT treatment in nine patients with advanced nonresectable cholangiocarcinoma. Bilirubin decreased in all patients, quality of life improved, and survival time was remarkably long.

    Article  PubMed  CAS  Google Scholar 

  45. Ortner MA: Photodynamic therapy of cholangiocarcinoma cancer. Gastrointest Endosc Clin North Am 2000, 10:481–486.

    CAS  Google Scholar 

  46. Berr F, Wiedmann M, Tannapfel A, et al.: Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000, 31:291–298. Twenty-three patients with nonresectable Bismuth type III and IV stenoses received photodynamic therapy with a hematoporphyrin derivative and a light flux of 240 J/cm2 in addition to endoprosthesis. This combined use resulted in an apparent benefit in survival time and improved quality of life.

    Article  PubMed  CAS  Google Scholar 

  47. Pahernik SA, Dellian M, Berr F, et al.: Distribution and pharmacokinetics of Photofrin in human bile duct cancer. J Photochem Photobiol 1998, 47:58–62.

    Article  CAS  Google Scholar 

  48. Zoepf TH, Jakobs R, Arnold J, et al.: Photodynamic therapy (PDT) for palliation of non-resectable bile duct cancer: first results with a new diode laser system [abstract]. Gastroenterology 1999, 116:A 536.

    Google Scholar 

  49. Wong Kee Song LM, Wang KK, Zinsmeister AR: Mono-Laspartyl chlorin e6 (NPe6) and hematoporphyrin derivate (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer 1998, 82:421–427. In nude mice inoculated with a human cholangiocarcinoma cell line, photodynamic therapy with HpD and NPe6 proved effective, according to this report.

    Article  PubMed  CAS  Google Scholar 

  50. Zoepf TH, Jakobs R, Rosenbaum A, et al.: Photodynamic therapy with 5-aminolaevulinic acid is NOT effective in bile duct cancer [abstract]. Gastroenterology 2000, 118:528.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endoscopy Unit, Department of Gastroenterology/Hepatology/ Endocrinology, Medical Faculty Charité, Campus Mitte, Humboldt University, Schumannstrasse 20-21, D-10117, Berlin, Germany

    Marianne Ortner MD

Authors
  1. Marianne Ortner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marianne, O. Photodynamic therapy in the biliary tract. Curr Gastroenterol Rep 3, 154–159 (2001). https://doi.org/10.1007/s11894-001-0013-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-001-0013-8

Keywords

Search

Navigation